Storys zum Thema Medicale

Fresenius Biotech

Catumaxomab, Representing a New Generation of Antibodies, Proved Efficient and Safe in Malignant Ascites / Data presented at 44th annual ASCO congress, Chicago, USA

München, Deutschland und Chicago, USA (ots) - Treatment with the trifunctional antibody catumaxomab significantly prolongs puncture-free survival in patients with malignant ascites, according to the results from a Phase II/III trial presented at the 44th American Society of Clinical Oncology (ASCO) congress. ...

Ergonex Pharma GmbH

Ergonex Pharma: Terguride receives FDA orphan drug designation for the treatment of pulmonary arterial hypertension

Appenzell (ots) - Ergonex Pharma today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to Terguride for the treatment of pulmonary arterial hypertension (PAH). Terguride is currently being evaluated for PAH in a pivotal Phase II trial in Europe. "The ...

Roche Professional Diagnostics

Roche Diagnostics expands availability of HCV immunoassay

Rotkreuz, Switzerland (ots) - Roche Diagnostics announced today that the Elecsys Anti-HCV (Hepatitis C Virus) assay has received regulatory approval in Europe for the E 170 analyzer for MODULAR ANALYTICS and the e 601 module for the cobas 6000 platform. The Elecsys Anti-HCV assay is already available on the Elecsys 2010 and the cobas e 411 instruments. Hepatitis C virus (HCV) infection represents a major cause ...

Mathys AG Bettlach

European Orthopaedic companies Mathys Ltd Bettlach and Lima-Lto S.p.A. sign Strategic Alliance

Solianis Monitoring AG

Continuous non-invasive glucose monitoring - Solianis Monitoring AG: Multi-sensor technology drives clinical progress

Zürich (ots) - Solianis sees its Multi-Sensor Technology as a promising approach to continuous non-invasive glucose monitoring. Professor Marc Donath, member of the Solianis Scientific Advisory Board and Professor for endocrinology and diabetology at the University Hospital in Zürich, Switzerland, has ...

Helsinn Healthcare SA

Helsinn Healthcare SA and Riemser Arzneimittel AG sign a license agreement for Aloxi® (palonosetron) and Gelclair® in Germany

Lugano (ots) - Helsinn Healthcare SA, a Swiss pharmaceutical group, today announced that it has signed a Distribution and License Agreement for Aloxi® (Palonosetron hydrochloride) and Gelclair® in Germany with Riemser Arzneimittel AG, a medium-sized pharmaceutical group engaging in research, headquartered in ...

Helsinn Healthcare SA

Helsinn Healthcare SA announces the launch of Aloxi® (Palonosetron) in the UK

Lugano, Switzerland (ots) - Helsinn Healthcare SA, a Swiss pharmaceutical group, is pleased to announce, ahead of schedule, today's launch in the UK of Aloxi® (Palonosetron hydrochloride), a new generation treatment for chemotherapy induced nausea and vomiting, by its local partner Maelor plc, the specialist hospital medicines group. Aloxi® is a patented ...

Anecova SA

The World Economic Forum announces Technology Pioneers 2008: The Swiss Anecova selected

Lausanne (ots) - The World Economic Forum has announced today the 39 visionary companies selected as Technology Pioneers 2008. Based in Lausanne, the Swiss company Anecova is one of them. The Technology Pioneers 2008 were nominated by the world's leading technology experts, including venture capitalists, technology companies, academics and media. The final selection ...

Helsinn Healthcare SA

Helsinn Healthcare and MGI PHARMA announce submission of supplemental new drug application for Aloxi® oral capsules

Lugano (ots) - Oral Formulations of 5-HT3 receptor Antagonists Represent Approximately 10% of the Day-of-Chemotherapy Market - Helsinn Healthcare SA, a privately owned Swiss pharmaceutical group, and its partner MGI PHARMA, INC., (Nasdaq: MOGN), a biopharmaceutical company focused in oncology and acute care, ...

Pieris AG

Pieris and Pepscan to identify GPCR-specific Anticalins® using CLIPS[TM] protein mimicry technology

Freising (ots) - Pieris AG (Munich, Germany) and Pepscan Therapeutics (Lelystad, Netherlands) today announced the commencement of a research collaboration aimed at identifying Anticalins® specific for G-Protein Coupled Receptors (GPCRs) and their development as therapeutic candidates. Pieris has pioneered ...

TRB Chemedica International S.A.

Paris court will rule on the distribution rights for Gilead products in Switzerland

Geneva (ots) - TRB Chemedica International S.A. has issued legal proceedings against Gilead Science Limited in a dispute over the distribution rights of their products Viread™, Hepsera™, Truvada™ and Emtriva™ for Switzerland. TRB Chemedica International S.A., a small, family-owned Swiss pharmaceutical company based in Geneva, was granted exclusive rights by ...

Grünenthal GmbH

Micropill Belara® improves impure skin

Paris (ots) - At this year's 7th congress of the European Society of Gynaecology (Paris, 10-14 October 2007), the German pharmaceutical company Grunenthal GmbH presents the latest study results for its oral contraceptive Belara®. As the first of its kind the dermatological CEFIS-Study* of the University of Hamburg shows an impressive cosmetic improvement of impured skin due to the anti-androgenic properties of ...

Prionics AG

Prionics enhances its European presence

Former Cedi-Diagnostics new affiliate for the Benelux and Nordic markets Zurich (ots) - Prionics, a world leader in farm animal diagnostics, enhances its own presence in Europe targeting the Benelux and Nordic markets with the launch of Prionics Lelystad (Netherlands). The latest affiliate emerges from the former Cedi-Diagnostics B.V. acquired in 2006, a spin-off from today's world-famous Animal Sciences Group of ...

Grünenthal GmbH

Centrally acting analgesic tapentadol - latest phase II data for the treatment of acute postoperative pain presented

Aachen (ots) - At this year's 4th World Congress of the World Institute of Pain (WIP), the German pharmaceutical company Grunenthal GmbH presented the latest clinical data on its centrally active analgesic tapentadol in acute pain. Tapentadol combines two analgesic principles in one molecule, μ-receptor ...

Spinelab AG

SpineLab and Precimed announce strategic partnership

Winterthur/Switzerland (ots) - SpineLab AG, a privately held company, specialized in developing a dynamic stabilization system for the spine, announced today the strategic partnership with Precimed Group, a leading technology-driven supplier to the orthopaedic industry. Under this agreement, Precimed co-develops the minimally invasive instrument set and will exclusively handle production and logistics for ...

Helsinn Healthcare SA

The CHMP/EMEA has confirmed that the benefit/risk profile of Nimesulide is positive

London (ots) - Helsinn's Top Management today announced the positive outcome of the EMEA procedure, according to Article 107, initiated due to concerns over serious liver problems. The Committee for Medicinal Products for Human Use (CHMP) today confirmed Nimesulide's positive benefit/risk profile. The benefits of these medicines outweigh their risks, but there ...

Krebsliga Schweiz

4th European Conference "Tobacco or Health" 2007; Invitation to the Media Conference, 11th October, 2007, Congress Center, Basel

Basel (ots) - The 4th European Conference "Tobacco or Health" takes place in Basel from 11th-13th October, 2007. The conference is organized by the Swiss Cancer League together with the German Cancer Society on behalf of the Association of European Cancer Leagues. About 800 participants from over 60 countries ...

Pieris AG

Pieris validates the use of Anticalins® as ophthalmologic biotherapeutics

Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced successful completion of a series of preclinical studies validating the use of Anticalins® in ophthalmologic disease. The studies reported by Pieris relate to PRS-055, an ...

Pieris AG

Pieris validates the use of Anticalins® as ophthalmologic biotherapeutics

Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced successful completion of a series of preclinical studies validating the use of Anticalins® in ophthalmologic disease. The studies reported by Pieris relate to PRS-055, an Anticalin® ...

Capio Diagnostics

Capio Announces Acquisition of Unilabs

- Transaction creates a leading laboratory services group in Europe operating under the name "Unilabs" - Binding purchase agreement signed with Unilabs' majority shareholders to acquire 50.08% of the Unilabs voting rights and 38.10% of the capital - Intention to launch public tender offer at CHF 57.50 per Unilabs bearer Unanimous support of transaction by Unilabs Board of Directors ...

Viroblock SA

Viroblock SA receives First Round of Equity Funding

Plan-les-Ouates (ots) - Viroblock SA, a start-up dedicated to developing and commercializing a new generation of antiviral products, today announced that it has completed its first round of equity funding led by private investor Peter Pfister, Fongit Seed Invest SA, and Initiative Capital Romandie SA. Viroblock also announced that the newly appointed Board of Directors will consist of Peter Pfister (Chairman), ...

Grünenthal GmbH

Grunenthal signs trimegestone licensing agreement for oral contraception

Aachen (ots) - The German pharmaceutical company Grunenthal announces its worldwide exclusive rights on trimegestone for the use in oral contraception by Aventis Pharma, SA, France, a subsidiary of sanofi-aventis. Thereby the firm extends its gynaecological pipeline. Trimegestone will be developed as a new oral contraceptive component derived from natural ...

European Society for Medical Oncology (ESMO)

ESMO Conference 5-8 July 2007, Lugano, Switzerland - Press Program

PLEASE NOTE: FULL TEXT OF THE PRESS RELEASES AVAILABLE THROUGH WWW.ESMO.ORG/PRESSROOM upon registration PLEASE RESPECT INDIVIDUAL EMBARGO DATES/TIMES FOUND ON FULL PRESS RELEASES Lugano (ots) - HORMONE INHIBITOR PROMISING FOR HARD-TO-TREAT PROSTATE CANCER For prostate cancer patients whose tumors have continued to grow despite medical or surgical castration, a new ...

Pieris AG

Pieris progresses development of its proprietary biotherapeutics platform: successful demonstration of dual targeting with Duocalin® technology

Freising-Weihenstephan, Germany (ots) - Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, announced today that its proprietary Duocalin® technology has successfully demonstrated dual targeting potential. Commenting on this development, Dr ...